Skip to main content
Clinical Trials/NCT07208370
NCT07208370Not yet recruitingNot Applicable

Outcome Predictors of Gillian Barrie Syndrome In Pediatrics

Assiut University1 site in 1 country80 target enrollmentStarted: October 1, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
80
Locations
1
Primary Endpoint
Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months

Study Overview

Brief Summary

This study analyze clinical and biological factors influencing disease course and outcome. Some research identified factors like disease severity, sensory symptoms, and autonomic instability as indicators of poor outcome. Ongoing research aims to develop accurate predictive models for improved treatment and care.

Detailed Description

Guillain-Barré Syndrome (GBS) is the most common cause of acute flaccid paralysis in children worldwide, often presenting with progressive weakness, areflexia, and varying degrees of autonomic and cranial nerve involvement. It is an immune-mediated disorder, commonly triggered by preceding infections such as Campylobacter jejuni, cytomegalovirus, or Epstein-Barr virus. Pediatric patients generally have a better prognosis than adults, yet a significant proportion still suffer from residual weakness or prolonged recovery. Understanding early predictors of outcome is essential for optimizing treatment and counseling families.[1][2] Several clinical and laboratory factors have been identified as potential predictors of poor outcomes in pediatric GBS. These include rapid progression to peak weakness, requirement of mechanical ventilation, presence of cranial nerve involvement (especially bulbar palsy), autonomic dysfunction, and the axonal subtypes of GBS on nerve conduction studies. Early identification of such factors allows for more aggressive supportive care and closer monitoring.[3][4][5] Electrophysiological classification also plays a vital role in predicting outcomes. Children with acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN) tend to have a slower and less complete recovery compared to those with acute inflammatory demyelinating polyneuropathy (AIDP). Furthermore, delayed initiation of immunotherapy such as intravenous immunoglobulin (IVIG) or plasma exchange may be associated with poorer prognosis.[6][7] Biomarkers like elevated cerebrospinal fluid (CSF) protein without pleocytosis (albuminocytologic dissociation) are typical in GBS but do not necessarily predict outcome. However, higher CSF protein levels in the early phase may correlate with more severe disease. Some recent studies have also suggested that MRI enhancement of spinal nerve roots may be associated with disease severity, although its prognostic value remains under investigation.[8][9] In conclusion, recognizing early outcome predictors in pediatric GBS is crucial for timely intervention, resource allocation, and family support. Although many children recover fully, identifying those at risk for complications can improve both short- and long-term care strategies.[2][3][10]

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
1 Month to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • All Pediatric patients (1 month to 18 years old) admitted with acute flaccid ascending paralysis and diagnosed as GBS.
  • Consent obtained from parents or legal guardians for participation and follow-up.

Exclusion Criteria

  • Children with pre-existing neuromuscular disorders. Patients with incomplete medical records or those lost to follow-up. Cases diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP).

Outcomes

Primary Outcomes

Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months

Time Frame: first 3 months after diagnosis

Proportion of pediatric patients with Guillain-Barré Syndrome achieving full recovery, as assessed by the Hughes Functional Grading Scale, within 3 months of diagnosis.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Nourhan Maher Fawzy

principal investigator

Assiut University

Study Sites (1)

Loading locations...

Similar Trials